• About
  Cedars-Sinai
• Careers at
  Cedars-Sinai
• Giving
  & Support
• Health
  Conditions
• Healthcare
  Professionals
• Patients
  & Visitors
• Programs
  & Services
• Quality
  Measures
• Research &
  Education

Below are breaking news items, news releases, patient education pieces and academic publications containing up-to-date information about cancer, medical advances, promising research studies and the Women's Cancer Research Institute at Cedars-Sinai Medical Center.

(You will need the Adobe® Reader® to view and print these documents from your desktop. If you do not have this software, you can download it FREE from Adobe's website.)

In this section, researchers from the Women's Cancer Research Institute will present their expert views on current research headlines.

• On September 7, 2005, Dr. Beth Karlan testified to the U.S. House of Representatives on behalf of H.R. 1245, the Gynecologic Cancer Education and Awareness Act of 2005 - commonly referred to as "Johanna's Law." Passage of Johanna's Law could immediately prevent needless deaths from gynecologic cancers. For a transcript of her testimony, click here.

• Women's Health Research Registry Now Online
  If you're interested in participating in clinical trials at Cedars-Sinai, please go to: www.cedars-sinai.edu/whrr
  

Click on the links below to read news stories that the Women's Cancer Research Institute has released to the media.

• Women Encouraged to Learn Their Family Health History During Gynecologic Cancer Awareness Month in September (August 21, 2006)

• Targeted Cancer Drug Combined with a Pill Form of Low-Dose Chemotherapy Found to Shrink Tumors and Slow Progression of Recurrent Ovarian Cancer (May 15, 2005)

The following are publications developed and printed by the Women's Cancer Research Institute.

• Today's Woman - Staying Healthy*

Below are academic articles published by our physicians.

• Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients with Advanced Cancer (April 2005) David B. Agus, Michael S. Gordon, Charles Taylor, Ronald B. Natale, Beth Karlan, David S. Mendelson, Michael F. Press, David E. Allison, Mark X. Sliwkowski, Gracie Lieberman, Stephen M. Kelsey and Gwen Fyfe
• Phase I Clinical and Pharmacokinetic Trial of Docetaxel and Irinotecan Administered on a Weekly Schedule (April 2005) Agustin A. Garcia, Mahesh Pujari, Susan Jeffers, Syma Iqbal, Heinz-Josef Lenz, Paul Beringer and Stan Louie
• Lower Urinary Tract Reconstruction with Ileum in the Treatment of Gynecologic Malignancies (February 2005) John C. Elkasa, Jonathan S. Berekb, Ronald Leuchterc, Leo D. Lagassec and Beth Y. Karlan

• Profiling the Perpetrator (December 2004) Beth Karlan
• Phase II Clinical Trial of Capecitabine in Ovarian Carcinoma Recurrent 6-12 Months after Completion of Primary Chemotherapy, with Exploratory TS, DPD and TP Correlates: A Gynecologic Oncology Group Study (December 2004) Agustin A. Garciaa, John A. Blessing, Heinz-Josef Lenzc, Kathleen M. Darcyd, Robert S. Mannele, David Scott Millerf and Nader Husseinzadeh
• The Colon Is a Pelvic Organ Too: Taking the Couric Challenge (November 2004) Beth Y. Karlan, MD
• Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature (February 2004) Alexander Liede, Beth Y. Karlan and Steven A. Narod
• Combining CA 125 and SMR Serum Markers for Diagnosis and Early Detection of Ovarian Carcinoma (2004) M.W. McIntosha, C. Dreschera, B. Karlanb, N. Schollera, N. Urbana, K.E. Hellstromc and I. Hellstrom
• Defining Cancer Risks for BRCA Germline Mutation Carriers: Implications for Surgical Prophylaxis (2004) An editorial by Beth Y. Karlan
• Phase II Study of Gemcitabine and Weekly Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer (2004) Agustin A. Garcia, Anne O'Meara, Ashim Bahador, Grace Facio, Susan Jeffers, Dae-Young Kim and Lynda Roman
• The Prognostic Significance of Thrombocytosis in Epithelial Ovarian Carcinoma (2004) Andrew J. Li, Alison C. Madden, Ilana Cass, Ronald S. Leuchter, Leo D. Lagasse and Beth Y. Karlan

• Short Androgen Receptor Allele Length Is a Poor Prognostic Factor in Epithelial Ovarian Carcinoma (September 2003) Andrew J. Li, Rae Lynn Baldwin and Beth Y. Karlan
• Estrogen and Progesterone Receptor Subtype Expression in Normal and Malignant Ovarian Epithelial Cell Cultures (July 2003) Andrew J. Li, MD; Rae Lynn Baldwin, PhD; and Beth Y. Karlan, MD
• Improved Survival in Women with BRCA-Associated Ovarian Carcinoma (May 2003) Ilana Cass, MD; Rae Lynn Baldwin, PhD; Taz Varkey, MD; Roxana Moslehi, PhD; Steven A. Narod, MD; and Beth Y. Karlan, MD
• Loss of c-myc Repression Coincides with Ovarian Cancer Resistance to Transforming Growth Factor B Growth Arrest Independent of Transforming Growth Factor B/Smad Signaling (March 2003) Rae Lynn Baldwin, Hang Tran and Beth Y. Karlan
• Overexpression of AKT2/Protein Kinase BB Leads to Up-Regulation of B1 Integrins, Increased Invasion and Metastasis of Human Breast and Ovarian Cancer Cells (January 2003) M. Jane Arboleda, John F. Lyons, Fairooz F. Kabbinavar, Mark R. Bray, Bryan E. Snow, Raul Ayala, Mordechai Danino, Beth Y. Karlan and Dennis J. Slamon
• Reproductive Factors and Ovarian Cancer Risk in Jewish BRCA1 and BRCA2 Mutation Carriers (2003) Francesmary Modugno, Roxana Moslehi, Roberta B. Ness, Deborah Brooks Nelson, Steven Belle, Jeffrey A. Kant, James E. Wheeler5, Aimee Wonderlick, David Fishman, Beth Karlan, Harvey Risch, Daniel W. Cramer,
  Marie-Pierre Dube and Steven A. Narod
• Evaluation of Recurrent Gastric Malignancy with [F-18]-FDG Positron Emission Tomography (2003) H. Jadvar, R. Tatlidil, A. A. Garcia and P. S. Conti
• Genetic Heterogeneity of Stably Transfected Cell Lines Revealed by Expression Profiling with Oligonucleotide Microarrays (2003) Min-Kyu Oh, Daniel R. Scoles, Carrie Haipek, Andrew D. Strand, David H. Gutmann, James M. Olson and Stefan-M. Pulst
• Molecular Similarities between Primary Peritoneal and Primary Ovarian Carcinomas (2003) L.-M. Chen, S. D. Yamada, Y.-S. Fu, R. L. Baldwin and B. Y. Karlan
• The Autosomal Recessive Juvenile Parkinson Disease Gene Product, Parkin, Interacts with and Ubiquitinates Synaptotagmin XI (2003) Duong P. Huynh, Daniel R. Scoles, Dung Nguyen and Stefan M. Pulst

• A Human Ovarian Carcinoma Murine Xenograft Model Useful for Preclinical Trials (October 2002) John C. Elkas, MD; Rae Lynn Baldwin, PhD; Mark Pegram, MD; Yiou Tseng, Dennis Slamon, MD, PhD; and Beth Y. Karlan, MD
• Periostin Secreted by Epithelial Ovarian Carcinoma Is a Ligand for aVB3 and aVB5
  Integrins and Promotes Cell Motility (September 2002) Lindsay Gillan, Daniela Matei, David A. Fishman, C. S. Gerbin, Beth Y. Karlan and David D. Chang
• Cancer Incidence in a Population of Jewish Women at Risk of Ovarian Cancer (March 2002) Alexander Liede, Beth Y. Karlan, Rae Lynn Baldwin, Lawrence D. Platt, Graciela Kuperstein and Steven A. Narod
• Generating Longitudinal Screening Algorithms Using Novel Biomarkers for Disease (February 2002) Martin W. McIntosh, Nicole Urban and Beth Karlan
• Effects of Nf2 Missense Mutations on Schwannomin Interactions (January 2002) Daniel R. Scoles, Mercy Chen and Stefan-M. Pulst
• A Phase I/II Trial of rAd/p53 (SCH 58500) Gene Replacement in Recurrent Ovarian Cancer (2002) Richard E Buller, Ingo B Runnebaum, Beth Y Karlan, Jo Ann Horowitz, Mark Shahin, Thomas Buekers, Stan Petrauskas, Rolf Kreienberg, Dennis Slamon and Mark Pegram
• Long-Term Follow-up of Patients with Recurrent Ovarian Cancer after Ad p53 Gene Replacement with SCH 58500 (2002) Richard E Buller, Mark S Shahin, Jo Ann Horowitz, Ingo B Runnebaum, Vikas Mahavni, Stan Petrauskas, Rolf Kreienberg, Beth Karlan, Dennis Slamon and Mark Pegram
• FIGO Stage III and IV Uterine Papillary Serous Carcinoma: Impact of Residual Disease on Survival (2002) S. Memarzadeh, C.H. Holschneider, R.E. Bristow, N.L. Jones, Y.S. Fu, B.Y. Karlan, J.S. Berek and R. Farias-Eisner
• Functional Analysis of the Relationship between the Neurofibromatosis 2 Tumor Suppressor and its Binding Partner, Hepatocyte Growth Factor-Regulated Tyrosine Kinase Substrate (2002) Chun-Xiao Sun, Carrie Haipek, Daniel R. Scoles, Stefan M. Pulst, Marco Giovannini, Masayuki Komada and David H. Gutmann
• Neurofibromatosis 2 (NF2) Tumor Suppressor Schwannomin and Its Interacting Protein HRS Regulate STAT Signaling (2002) Daniel R. Scoles, Vu D. Nguyen, Yun Qin, Chun-Xiao Sun, Helen Morrison, David H. Gutmann and Stefan-M. Pulst
• Phase I Escalation of Gemcitabine Combined with Protracted Oral Etoposide in Gynecologic Malignancies (2002) Agustin A. Garcia, Michael A. Bookman, Lorna Rodriguez-Rodriguez, David G. Mutch and Katherine Y. Look
• Gene Expression in Epithelial Ovarian Carcinoma (2002) Daniela Matei, Thomas G Graeber, Rae Lynn Baldwin, Beth Y Karlan, Jianyu Rao and David D Chang

• Phase I and Pharmacologic Study of IV Hydroxyurea Infusion Given with IP 5-Fluoro-2'-Deoxyuridine and Leucovorin (December 2001) Agustin A Garcia, Franco M Muggia, C Paul Spears, Susan Jeffers, Howard Silberman, Mahesh Pujari and Robert T Koda
• Allelotype of Papillary Serous Peritoneal Carcinomas (May 2001) Ilana Cass, MD; Rae Lynn Baldwin, PhD; Ella Fasylova, MD; Abbie L. Fields, MD; Harold P. Klinger, MD, PhD; Carolyn D. Runowicz, MD; and Beth Y. Karlan, MD
• Tubal Ligation and Risk of Ovarian Cancer in Carriers of BRCA1 or BRCA2 Mutations: A Case-Control Study (May 2001) Steven A Narod, Ping Sun, Parviz Ghadirian, Henry Lynch, Claudine Isaacs, Judy Garber, Barbara Weber, Beth Karlan, David Fishman, Barry Rosen, Nadine Tung, Susan L Neuhausen and the Hereditary Ovarian Cancer Clinical Study Group
• Phase II Trial of Outpatient Schedule of Paclitaxel in Patients with Previously Untreated Metastatic, Measurable Adenocarcinoma of the Stomach (2001) Agustin A. Garcia, Cynthia G. Leichman, Heinz Josef Lenz, Joaquina Baranda, Ramona Lujan, Yolee Casagrande and Lawrence Leichman
• The NF2 Interactor, Hepatocyte Growth Factor-Regulated Tyrosine Kinase Substrate (HRS), Associates with Merlin in the Open Conformation and Suppresses Cell Growth and Motility (2001) David H. Gutmann, Carrie A. Haipek, Stephen P. Burke, Chun-Xiao Sun, Daniel R. Scoles and Stefan M-Pulst
• Progesterone Receptor Variant Increases Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers Who Were Never Exposed to Oral Contraceptives (2001) Ingo B. Runnebaum, Shan Wang-Gohrke, Danny Vesprini, Rolf Kreienberg, Henry Lynch, Roxana Moslehi, Parviz Ghadirian, Barbara Weber, Andrew K. Godwin, Harvey Risch, Judy Garber, Caryn Lerman, Olufunmilayo I. Olopade, William D. Foulkes, Beth Karlan, Ellen Warner, Barry Rosen, Timothy Rebbeck, Patricia Tonin, Marie-Pierre Dube, Dirk G. Kieback and Steven A. Narod